Althea enters commercial drug supply agreement with Biotest

NewsGuard 100/100 Score
May 3 2011

Althea Technologies, Inc. announced today that they have entered into a commercial supply agreement with Biotest Pharmaceuticals Corporation.  Under the terms of the agreement, Althea will fill commercial drug products to supply the U.S. market.  The products will be filled in Althea's new commercial manufacturing facility in San Diego.

"We are very pleased to be selected by Biotest as their strategic partner and commercial filler," stated Rick Hancock, President, Althea Technologies.  "We are looking forward to supporting Biotest as their commercial manufacturing partner."

Source:

Althea Technologies, Inc.

Posted in: Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

ArgusEye closes €2.8 million funding to accelerate bioprocessing
LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities
New collaboration to combat river blindness and lymphatic filariasis
Researchers receive NIH grant to help develop gene therapy for HIV
Lab to plant: Scaling up API processes with Dr. James Mencel's guidance
Early feasibility studies on climate-friendly albuterol inhaler completed
Navigating the complexities of controlled release drug formulations
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service